During the last session, Revance Therapeutics Inc. (NASDAQ:RVNC)’s traded shares were 0.51 million, with the beta value of the company hitting 0.84. At the end of the trading day, the stock’s price was $13.65, reflecting an intraday loss of -0.22% or -$0.03. The 52-week high for the RVNC share is $33.83, that puts it down -147.84 from that peak though still a striking 4.69% gain since the share price plummeted to a 52-week low of $13.01. The company’s market capitalization is $1.01B, and the average intraday trading volume over the past 10 days was 1.16 million shares, and the average trade volume was 1.18 million shares over the past three months.
Revance Therapeutics Inc. (RVNC) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.70. RVNC has a Sell rating from 0 analyst(s) out of 10 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 9 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$1.15.
3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Revance Therapeutics Inc. (RVNC) registered a -0.22% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.22% in intraday trading to $13.65 this Wednesday, 11/24/21, hitting a weekly high. The stock’s 5-day price performance is -3.60%, and it has moved by -2.57% in 30 days. Based on these gigs, the overall price performance for the year is -41.69%. The short interest in Revance Therapeutics Inc. (NASDAQ:RVNC) is 3.69 million shares and it means that shorts have 12.14 day(s) to cover.
The consensus price target of analysts on Wall Street is $28.10, which implies an increase of 51.42% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $17.00 and $55.00 respectively. As a result, RVNC is trading at a discount of -302.93% off the target high and -24.54% off the low.
Revance Therapeutics Inc. (RVNC) estimates and forecasts
Statistics show that Revance Therapeutics Inc. has outperformed its competitors in share price, compared to the industry in which it operates. Revance Therapeutics Inc. (RVNC) shares have gone down -53.99% during the last six months, with a year-to-date growth rate more than the industry average at 15.02% against 7.90. Yet analysts are ramping up their growth forecast for the fiscal year 2021. Revenue is predicted to grow 14.20% this quarter and then jump 1.60% in the quarter after that. In the rating firms’ projections, revenue will increase 447.90% compared to the previous financial year.
Revenue for the current quarter is expected to be $21.15 million as predicted by 9 analyst(s). Meanwhile, a consensus of 9 analyst(s) estimates revenue growth to $31.56 million by the end of Dec 2021. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $3.83 million and $11.13 million respectively. In this case, analysts expect current quarter sales to grow by 451.50% and then jump by 183.50% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -10.00%. While earnings are projected to return -32.60% in 2021, the next five years will return 11.60% per annum.
Revance Therapeutics Inc. is due to release its next quarterly earnings between February 21 and February 25. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Revance Therapeutics Inc. (NASDAQ:RVNC)’s Major holders
Revance Therapeutics Inc. insiders own 2.86% of total outstanding shares while institutional holders control 88.92%, with the float percentage being 91.54%. Blackrock Inc. is the largest shareholder of the company, while 250 institutions own stock in it. As of Jun 29, 2021, the company held over 5.35 million shares (or 7.44% of all shares), a total value of $158.51 million in shares.
The next largest institutional holding, with 5.04 million shares, is of JP Morgan Chase & Company’s that is approximately 7.02% of outstanding shares. At the market price on Jun 29, 2021, these shares were valued at $149.49 million.
Also, the Mutual Funds coming in first place with the largest holdings of Revance Therapeutics Inc. (RVNC) shares are Smallcap World Fund and Vanguard Total Stock Market Index Fund. Data provided on Jun 29, 2021 indicates that Smallcap World Fund owns about 4.51 million shares. This amounts to just over 6.28 percent of the company’s overall shares, with a $133.75 million market value. The same data shows that the other fund manager holds slightly less at 1.92 million, or about 2.68% of the stock, which is worth about $57.05 million.